CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation.

Xiaoliang HuaJiong ZhangShengdong GeHaoran LiuHe-Xi DuQingsong NiuXianguo ChenCheng YangLi Zhang Chao-Zhao Liang

Published in: The Prostate (2022)

CXCR3 antagonist AMG487 could ameliorate the inflammatory changes and the pelvic pain of EAP mice by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation. Thus, the results imply that AMG487 has the potential as an effective therapeutic agent in the prevention and treatment of EAP.

Keyphrases

signaling pathway
adipose tissue
chronic pain
multiple sclerosis
pain management
cell migration
oxidative stress
neuropathic pain
mouse model
type diabetes
metabolic syndrome